Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis.
Agnogenic myeloid metaplasia (AMM) is characterized by bone marrow fibrosis with abnormal accumulation of extracellular matrix components (ECM), which is dependent on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Twenty-five patients with AMM, 30 with essential thrombocythemia (ET), 12 with polycythemia vera (PV) and 20 normal control subjects were studied. AMM patients had decreased plasma levels of MMP-3 and marked elevated levels of TIMP-1, but MMP-1, MMP-2 and MMP-9 levels were not significantly different from control subjects. Elevated levels of plasma TIMP-1, but not MMPs, were found in ET and PV. Reduced MMP activity together with increased TIMP-1 activity may be essential in fibrosis formation.
Wang
Jen C
JC
Division of Hematology and Oncology, Maimonides Medical Center, Brookdale University Hospital, Brooklyn, New York 11219, USA. jcwang5@aol.com
Novetsky
Akiva
A
Chen
Chi
C
Novetsky
Allan D
AD
D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D008875:Middle Aged; D011087:Polycythemia Vera / Q000097:blood; D055728:Primary Myelofibrosis / Q000097:blood*; D013920:Thrombocythemia, Essential / Q000097:blood; D013922:Thrombocytosis / Q000097:blood; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*
D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases